http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-365089-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73ee0bacab5a7576a6a3244747f6ea99 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-425 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 |
| filingDate | 1969-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1971-01-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-365089-A1 |
| titleOfInvention | PROCEDURE FOR THE PREPARATION OF THIAZOLIC DERIVATIVES. |
| abstract | Pharmaceutical compositions having antiinflammatory, analgesic and anti-pyretic activity comprise, as active ingredient, at least one [alpha]-thiazolyl-malonic acid derivative of the general formula wherein Y or Z is linked to the 2-position of the thiazole nucleus, X is a hydrogen atom or a C 1-3 alkyl group, Y is a phenyl group optionally substituted by 'up to two halogen atoms selected from fluorine, chlorine or bromine, and Z is a group of the formula wherein R1 is a hydrogen or alkali metal atom, a C 1-3 alkyl group, a dialkylaminomethyl group of up to 5 carbon atoms, a piperidinomethyl or morpholinomethyl group, or a chlorine or bromine atom, and R2 and R3 are each a hydrogen atom or a C 1-3 alkyl group, provided that, when R2 and R3 are each a hydrogen atom, R1 is a hydrogen atom or a C 1-3 alkyl group, a tautomer thereof or a non-toxic, pharmaceutically-acceptable salt thereof, togothler with a non-toxic, pharmaceuticallyacceptable diluent or carrier. The compositions may be administered orally, parenterally, topically or rectally in the form of tablets, pills, capsules, suppositories, non-sterile aqueous or non-aqueous solutions or suspensions, sterile injectable aqueous or non-aqueous solutions or suspensions, creams, lotions or ointments. The compositions may additionally contain at least one known anti-inflammatory or analgesic agent, e.g. aspirin, paracetamol, codeine, chloroquine, phenylbutazone, oxyphenbutazone, indomethacin, mefenamic acid, flufenamic acid or ibufenac, or an anti-inflammatory . steroid, such as prednisolone. Compositions intended for oral administration may additionally contain an anti-cholinergic agent, e.g. homatropine methyl bromide, and/or an antacid, e.g. aluminium hydroxide, or a uricosuric agent, e.g. probenecid. Compositions suitable for topical application may additionally contain a vasodilating agent, eg. tolazoline, or a vasoconstricting agent, e.g. adrenaline a local anaesthetic, e.g. amethocaine, a counter-irritant, e.g. capsicum, and/or at least one agent chosen from 'antibacterial agents, such as sulphonamides and antibiotics having antibacterial action, e.g. neomycin anti-fungal agents, e.g. hydroxyquinoline .antihistaminic agents, e.g. promethazine, and rubefacient agents, e.g. methyl nicotinate. |
| priorityDate | 1968-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 83.